Celldex Therapeutics (NASDAQ:CLDX) Price Target Raised to $72.00

Celldex Therapeutics (NASDAQ:CLDX) had its price target boosted by Cantor Fitzgerald from $61.00 to $72.00 in a research report released on Tuesday,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the biopharmaceutical company’s stock.

A number of other analysts have also issued reports on CLDX. Barclays lifted their price objective on shares of Celldex Therapeutics from $48.00 to $53.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. UBS Group lifted their price target on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Wells Fargo & Company boosted their price objective on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Canaccord Genuity Group decreased their price objective on shares of Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Finally, HC Wainwright restated a “buy” rating and set a $42.00 target price on shares of Celldex Therapeutics in a research note on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.92.

Celldex Therapeutics Price Performance

Shares of CLDX opened at $31.48 on Tuesday. Celldex Therapeutics has a 12 month low of $22.10 and a 12 month high of $45.14. The stock’s 50-day moving average is $38.81 and its two-hundred day moving average is $34.86. The stock has a market cap of $2.47 billion, a PE ratio of -7.24 and a beta of 0.84.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.12. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.73 million. On average, research analysts anticipate that Celldex Therapeutics will post -4.17 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Nykredit A S bought a new stake in shares of Celldex Therapeutics in the 2nd quarter worth about $67,000. Diversified Trust Co acquired a new position in Celldex Therapeutics in the first quarter worth about $223,000. Walleye Capital LLC acquired a new position in Celldex Therapeutics in the first quarter worth about $258,000. Amundi bought a new stake in Celldex Therapeutics in the first quarter valued at about $297,000. Finally, Glenmede Trust Co. NA bought a new stake in Celldex Therapeutics in the first quarter valued at about $357,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for diseases with significant unmet medical needs. The company’s research programs address conditions in immunology, inflammation, oncology and other areas where targeted immune-system modulation may provide therapeutic benefits.

Celldex’s lead investigational product is barzolvolimab, an antibody designed to block the KIT receptor and reduce mast cells. The therapy is being studied in immune-mediated diseases, including chronic spontaneous urticaria and prurigo nodularis.